Serum soluble TWEAK levels in non-alcoholic fatty liver disease

Basit Öğe Kaydı
dc.authoridRamazan Dertli: 0000-0002-6205-8983
dc.authoridMuharrem Keskin: 0000-0002-5696-4752
dc.authoridHüseyin Ataseven: 0000-0001-8515-8760
dc.authoridMehmet Asıl: 0000-0001-7332-686X
dc.authoridSaliha Uysal: 0000-0002-9815-1039
dc.contributor.authorDertli, Ramazan
dc.contributor.authorYolaçan, Ramazan
dc.contributor.authorKeskin, Muharrem
dc.contributor.authorKayar, Yusuf
dc.contributor.authorAtaseven, Hüseyin
dc.contributor.authorPolat, Hakkı
dc.contributor.authorÜnver, Nurcan
dc.contributor.authorDemir, Ali
dc.contributor.authorAsıl, Mehmet
dc.contributor.authorBıyık, Murat
dc.contributor.authorUysal, Saliha
dc.date.accessioned2020-01-18T21:03:14Z
dc.date.available2020-01-18T21:03:14Z
dc.date.issued2019
dc.departmentNEÜ, Meram Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalıen_US
dc.description.abstractAim: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. The exact pathogenesis of NAFLD has not been fully elucidated. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of TNF superfamily and it hasbeen implicated in the pathogenesis of several diseases including liver inflammation and fibrosis. Current study was conducted to evaluate serum sTWEAK levels in patients with NAFLD. Material and Methods: Seventeen patients with biopsy proven non-alcoholic steatohepatitis (NASH), 22 patients with simple hepatosteatosis and 30 healthy controls were included in the study and serum sTWEAK concentrations were measured using commercial ELISA kits. Results: Mean serum sTWEAK concentration was significantly lower in the NASH group when compared to the simple hepatosteatosis group and healthy controls (199.6101.2 pg/mL, 246.165.7 pg/mL and 277.6117.6 pg/mL respectively, p0.029). ROC analysesfor sTWEAK to differentiate NASH patients from healthy controls and from simple hepatosteatosis revealed that AUC for sTWEAK was 0.712 (%95 CI, 0.543-0.880). For the specified cut off value, 171.1 pg/mL positive and negative predictive values calculated were 64.3% and 85.5% respectively. Conclusion: Serum sTWEAK concentration is decreased in patients with NASH when compared to patients with simple hepatosteatosis and healthy controls.en_US
dc.identifier.citationDertli, R., Yolaçan, R., Keskin, M., Kayar, Y., Ataseven, H., Polat, H., Ünver, N., Demir, A., Asıl, M., Bıyık, M., Uysal, S. (2019). Serum soluble TWEAK levels in non-alcoholic fatty liver disease. Annals of Medical Research, 26, 8, 1594-1599.
dc.identifier.doi10.5455/annalsmedres.2019.05.248en_US
dc.identifier.endpage1599en_US
dc.identifier.issn2636-7688en_US
dc.identifier.issn2636-7688en_US
dc.identifier.issue8en_US
dc.identifier.startpage1594en_US
dc.identifier.urihttps://dx.doi.org/10.5455/annalsmedres.2019.05.248
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpFM05UWTJOZz09/serum-soluble-tweak-levels-in-non-alcoholic-fatty-liver-disease
dc.identifier.urihttps://hdl.handle.net/20.500.12452/1508
dc.identifier.volume26en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US]
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNonalcoholic steatohepatitisen_US
dc.subjectTumor necrosis factor-like weak inducer of apoptosisen_US
dc.subjectsTWEAKen_US
dc.subjectFibroblast growth factor-inducible 14en_US
dc.subjectFn 14en_US
dc.titleSerum soluble TWEAK levels in non-alcoholic fatty liver diseaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Serum soluble TWEAK levels in non-alcoholic fatty liver disease.pdf
Boyut:
277.15 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin (Full Text)
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu